Simmunext secures NWO Take-off Phase 2 funding. Simmunext has secured funding from the Dutch Research Council (NWO) in the context of the Take-off Phase 2 program, which aims to stimulate and support activities and entrepreneurship towards applied sciences. The awarded project focuses on the application of immunofilaments (IF) in cancer. IF are proprietary polymers coupled … Read more
Simmunext Biotherapeutics is proud to announce its participation in the prestigious BioEquity Europe Meeting, scheduled to be held from May 12 to 14 in San Sebastian, Spain. As a leading biotechnology company dedicated to advancing the frontiers of immunotherapy, Simmunext is set to present its groundbreaking research and development initiatives on immunofilaments, aimed at revolutionizing … Read more
Simmunext will be presenting at the Radboudumc Investment Day Get ready for the third edition of Radboudumc Investment Day 2023 on October 12 in Nijmegen! Jointly organized by Radboudumc, Radboud University, Briskr and Oost NL, the Investment Day is a matchmaking event for investors, entrepreneurs and top researchers in the life sciences & health domain. … Read more
Direct In Vivo Activation of T Cells with Nanosized Immunofilaments Inhibits Tumor Growth and Metastasis Weiss L, Weiden J, Dolen Y, Grad EM, van Dinther EAW, Schluck, M, Eggermont, LJ, van Mierlo G, Gileadi U, Bartolo-Ibars A, Raave R, Gorris MAJ, Maassen L, Verrijp K, Valente M, Deplancke B, Verdoes M, Benitez-Ribas D, Heskamp S, … Read more
Dictating Phenotype, Function, and Fate of Human T Cells with Co-Stimulatory Antibodies Presented by Filamentous Immune Cell Mimics Schluck M, Eggermont LJ, Weiden J, Popelier C, Weiss L, Pilzecker B, Kolder S, Heinemans A, Rodriguez Mogeda C, Verdoes M, Figdor CG and Hammink R.; Adv. Therap. 2022, DOI 2200019.
Financiering voor Simmunext: nieuwe therapie voor de behandeling van kanker. Met een investering vanuit het Vroege fase financiering Gelderland (VFF Gelderland) kan het Nijmeegse Simmunext Biotherapeutics BV verder met de ontwikkeling van een nieuwe behandeling voor kanker. Het bedrijf gebruikt de financiering om de werking van het medicijn verder te onderzoeken. Oost NL is fondsmanager … Read more
Radboudumc researchers publish on the scientific evidence for the inhibition of tumor growth and metastasis using immunofilaments in preclinical model systems. Adoptive T cell therapy has successfully been implemented for the treatment of cancer. Nevertheless, ex vivo expansion of T cells by artificial antigen-presenting cells (aAPCs) remains cumbersome and can compromise T cell functionality, thereby … Read more
Semiflexible Immunobrushes Induce Enhanced T Cell Activation and Expansion: Hammink R, Weiden J, Voerman D, Popelier C, Eggermont LJ, Schluck M, Figdor CG and Verdoes M.; ACS Appl. Mater. Interfaces, 2021, 13, 14, 16007.
Synthetic Semiflexible and Bioactive Brushes: Voerman D, Schluck M, Weiden J, Joosten B, Eggermont LJ, van den Eijnde T, Ignacio B, Cambi A, Figdor CG, Kouwer PHJ, Verdoes M, Hammink R. and Rowan AE.; Biomacromolecules, 2019, 20, 2587.
Cytokine-functionalized Synthetic Dendritic Cells for T Cell Targeted Immunotherapies: Eggermont LJ, Hammink R, Blank KG, Rowan AE, Tel J, and Figdor CG.; Adv. Therap, 2018, DOI1800021.